| Literature DB >> 34294905 |
Abbas El Sahili1,2, Matthew Zirui Tay3,4, Guillaume Carissimo3,4, Bruce Russell5,6, Laurent Rénia7,8,9, Benoît Malleret10,11,12, Alice Soh Meoy Ong3,4, Wisna Novera13, Jianqing Lin1,4, Rossarin Suwanarusk3,6, Varakorn Kosaisavee5,6,14, Trang T T Chu15, Ameya Sinha15, Shanshan Wu Howland3, Yiping Fan16,17, Jakub Gruszczyk18, Wai-Hong Tham18,19, Yves Colin20,21, Sebastian Maurer-Stroh4,22,23, Georges Snounou24, Lisa F P Ng3,4, Jerry Kok Yen Chan16,17,25, Ann-Marie Chacko13, Julien Lescar1,2, Rajesh Chandramohanadas5,15, François Nosten26,27.
Abstract
More than one-third of the world's population is exposed to Plasmodium vivax malaria, mainly in Asia1. P. vivax preferentially invades reticulocytes (immature red blood cells)2-4. Previous work has identified 11 parasite proteins involved in reticulocyte invasion, including erythrocyte binding protein 2 (ref. 5) and the reticulocyte-binding proteins (PvRBPs)6-10. PvRBP2b binds to the transferrin receptor CD71 (ref. 11), which is selectively expressed on immature reticulocytes12. Here, we identified CD98 heavy chain (CD98), a heteromeric amino acid transporter from the SLC3 family (also known as SLCA2), as a reticulocyte-specific receptor for the PvRBP2a parasite ligand using mass spectrometry, flow cytometry, biochemical and parasite invasion assays. We characterized the expression level of CD98 at the surface of immature reticulocytes (CD71+) and identified an interaction between CD98 and PvRBP2a expressed at the merozoite surface. Our results identify CD98 as an additional host membrane protein, besides CD71, that is directly associated with P. vivax reticulocyte tropism. These findings highlight the potential of using PvRBP2a as a vaccine target against P. vivax malaria.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34294905 DOI: 10.1038/s41564-021-00939-3
Source DB: PubMed Journal: Nat Microbiol ISSN: 2058-5276 Impact factor: 17.745